Too little information—or, specifically, missing information, according to Bloomberg—prompted the FDA to reject Johnson & Johnson’s request to expand the indication for the company’s blood thinner Xarelto.
The drugmaker wanted the drug to be used to reduce blood clots in coronary artery disease patients. Friday’s rejection marked a third miss for this indication.
